Alimera to Present at the June 2020 Virtual Summer Investor Summit
Alimera Sciences (NASDAQ: ALIM) announced that CEO Rick Eiswirth will present at the June 2020 Virtual Summer Investor Summit from June 9-12, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alimera Sciences (NASDAQ: ALIM) announced that CEO Rick Eiswirth will present at the June 2020 Virtual Summer Investor Summit from June 9-12, 2020. The corporate presentation is scheduled for June 9 at 3:55 pm ET, followed by a live Q&A session with investors. A live webcast will be available here. Investors can also request one-on-one meetings with Eiswirth via email. Alimera specializes in developing treatments for retinal diseases, addressing significant unmet needs in ophthalmology.
Details
News Market Reaction – ALIM
The recorded move for ALIM in the trading session of this news was -0.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, June 03, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, Alimera’s President and Chief Executive Officer will give a corporate presentation at the June 2020 Virtual Summer Investor Summit taking place online from June 9- 12, 2020.
The presentation will be held on Tuesday, June 9, 2020 at 3:55 pm ET, followed by a live Q&A session with registered investors and other conference attendees. A live webcast of the presentation will be available here https://www.webcaster4.com/Webcast/Page/2038/35019. Mr. Eiswirth will be available for one-on-one meetings online as well. Interested investors may request a meeting time by emailing laura@investorsummitgroup.com.
About Alimera Sciences, Inc.
Alimera is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people globally. For more information, please visit www.alimerasciences.com.
| For investor inquiries: | For media inquiries: |
| Scott Gordon | Jules Abraham |
| for Alimera Sciences | for Alimera Sciences |
| scottg@coreir.com | julesa@coreir.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.